John Bishop - Momenta Pharmaceuticals Senior Vice President - Pharmaceutical Sciences
President
Dr. John E. Bishop Ph.D. is the Senior Vice President Pharmaceutical Sciences of Momenta Pharmaceuticals Inc since December 2006. He served as our Vice President Pharmaceutical Sciences and Manufacturing from November 2004 to December 2006 since 2006.
Age | 53 |
Tenure | 18 years |
Professional Marks | MBA |
Phone | 617 621-0431 |
Web | www.momentapharma.com |
Momenta Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (30.56) % which means that it has lost $30.56 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (64.36) %, meaning that it created substantial loss on money invested by shareholders. Momenta Pharmaceuticals' management efficiency ratios could be used to measure how well Momenta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 37.09 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Momenta Pharmaceuticals has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Momenta Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Momenta Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Momenta Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Momenta to invest in growth at high rates of return. When we think about Momenta Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Rick Nechio | Fresh Grapes LLC | 46 | |
Ricardo Moreira | Anheuser Busch Inbev | 50 | |
Ricardo Tadeu | Anheuser Busch Inbev | 48 | |
Reinald Siswanto | Vita Coco | 33 | |
Joao Neves | Anheuser Busch Inbev | 49 | |
Emily Whittaker | Cimpress NV | N/A | |
Stuart MacFarlane | Anheuser Busch Inbev | 50 | |
Mauricio Arboleda | Anheuser Busch Inbev | 47 | |
Jean Jereissati | Anheuser Busch Inbev | 46 | |
Sean Quinn | Cimpress NV | 45 | |
Graham Staley | Anheuser Busch Inbev | N/A | |
Lawrence Gold | Cimpress NV | 47 | |
Katryn Blake | Cimpress NV | 43 | |
Jean Neto | Anheuser Busch Inbev | 50 | |
Jan Craps | Anheuser Busch Inbev | 47 | |
Luiz Edmond | Anheuser Busch Inbev | 49 | |
Michel Doukeris | Anheuser Busch Inbev | 51 | |
Carlos Lisboa | Anheuser Busch Inbev | 55 | |
Ashley Hubka | Cimpress NV | 42 | |
Jason Warner | Anheuser Busch Inbev | 48 | |
Donny Hartanto | Vita Coco | 37 |
Management Performance
Return On Equity | -64.36 | |||
Return On Asset | -30.56 |
Momenta Pharmaceuticals Leadership Team
Elected by the shareholders, the Momenta Pharmaceuticals' board of directors comprises two types of representatives: Momenta Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Momenta. The board's role is to monitor Momenta Pharmaceuticals' management team and ensure that shareholders' interests are well served. Momenta Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Momenta Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Bennett Shapiro, Independent Director | ||
James Anderson, Senior Vice President - Pharmaceutical Sciences | ||
Craig Wheeler, CEO and President and Executive Director | ||
Georges Gemayel, Director | ||
Matthew Ottmer, COO | ||
Alejandra Carvajal, Chief Legal Officer, General Counsel and Secretary | ||
Elizabeth Stoner, Independent Director | ||
Michelle Robertson, CFO, Principal Financial Officer and Principal Accounting Officer | ||
John Bishop, Senior Vice President - Pharmaceutical Sciences | ||
JoseCarlos GutierrezRamos, Director | ||
Bruce Leicher, Senior Vice President General Counsel, Secretary | ||
James Sulat, Independent Chairman of the Board | ||
Corey Fishman, Director | ||
Jim Anderson, Senior Vice President - Pharmaceutical Sciences | ||
Santiago Arroyo, Senior Vice President Development and Chief Medical Officer | ||
James Roach, Senior Vice President - Development, Chief Medical Officer | ||
Young Kwon, Senior Vice President - Corporate Development and Strategy | ||
Bruce Downey, Independent Director | ||
JoAnn Beltramello, Senior Vice President - Human Resources | ||
Steven Gilman, Director | ||
Anthony Manning, Senior Vice President - Research | ||
Marsha Fanucci, Independent Director | ||
Ganesh Kaundinya, Co-Founder, Chief Scientific Officer and Sr. VP of Research | ||
Ian Fier, Senior Vice President - Program and Project Management | ||
Richard Shea, CFO, Sr. VP and Treasurer | ||
Michael Franken, President - Biosimilars Business, Senior Vice President | ||
Thomas Koestler, Independent Director | ||
Scott Storer, CFO, Senior Vice President |
Momenta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Momenta Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -64.36 | |||
Return On Asset | -30.56 | |||
Operating Margin | (815.34) % | |||
Current Valuation | 5.71 B | |||
Shares Outstanding | 118.97 M | |||
Shares Owned By Insiders | 0.98 % | |||
Shares Owned By Institutions | 99.02 % | |||
Number Of Shares Shorted | 5.41 M | |||
Price To Earning | (7.85) X | |||
Price To Book | 15.41 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Momenta Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Momenta Pharmaceuticals' short interest history, or implied volatility extrapolated from Momenta Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Momenta Stock
If you are still planning to invest in Momenta Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Momenta Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |